CRP and urinary bladder cancer: While CRP ≥ 0.5 mg/dL was associated with intravesical recurrence, poorer CSS, and bladder cancer progression in uni- and multivariate analysis, NLR ≥ 2.5 was not associated with any of these clinical outcomes [65].